(Press-News.org) London, United Kingdom, Friday 11 April 2014: New research announced at the International Liver CongressTM 2014 today provides new hope for the notoriously difficult-to-treat population of liver transplant patients with recurring hepatitis C (HCV).
As part of a compassionate use program, 104 post-liver transplant patients with recurring HCV who had exhausted all treatment options and had poor clinical prognoses, received sofosbuvir (SOF) and ribavirin (RBV) with pegylated interferon (PEG) included at the physicians’ discretion for up to 48 weeks. Among patients whose clinical outcomes have been reported, 62% achieved SVR12. Additionally, 62% of patients had improvements in clinical conditions associated with hepatic decompensation (e.g., ascites and encephalopathy) and/or improvement in liver function tests. SOF+RBV±PEG was well-tolerated and led to high rates of virologic suppression.
EASL’s European Policy Councillor Professor Patrizia Burra of the Multivisceral Transplant Unit, Padova University Hospital, Padua, Italy said: “There are currently no effective treatment options for this patient group. However, this new trial involving the nucleotide polymerase inhibitor sofosbuvir (SOF) has demonstrated promising results, providing further evidence of its clinical potential.”
“For patients with advanced hepatitis C liver disease, liver transplants offer a second chance,” continued Professor Burra, “and for those who continue to suffer post-surgery, it’s important for us to keep following up all avenues possible to improve their quality of life.”
Other research revealed at the International Liver CongressTM 2014 showed that most patients with mild hepatitis C recurrence diagnosed one year after liver transplant have excellent long-term outcomes.
In the second study, 172 patients who were diagnosed with mild hepatitis C recurrence one year after undergoing liver transplant surgery between 1999 and 2012 were followed for six and a half years with all relevant transplant-related, donor and recipient variables recorded. The cumulative probability of HCV-related graft loss five and 10 years after liver transplant were 3% and 10%, respectively.
However one third of these patients are still at risk of going on to develop cirrhosis, further demonstrating the need for antiviral therapy pre or post-transplant.
Hepatitis C infection is a common cause of liver transplantation, with virus-related diseases comprising 40% of primary indications for liver transplantation in Europe among patients with cirrhosis.
More than 5,500 liver transplantations are currently performed in Europe per year.3
Disclaimer: the data referenced in this release is based on the submitted abstract. More recent data may be presented at the International Liver Congress™ 2014.
INFORMATION:
Notes to Editors
About EASL
EASL is the leading European scientific society involved in promoting research and education in hepatology. EASL attracts the foremost hepatology experts and has an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in European liver policy.
EASL's main focus on education and research is delivered through numerous events and initiatives, including:
The International Liver CongressTM which is the main scientific and professional event in hepatology worldwide
Meetings including Monothematic and Special conferences, Post Graduate courses and other endorsed meetings that take place throughout the year
Clinical and Basic Schools of Hepatology, a series of events covering different aspects in the field of hepatology
Journal of Hepatology published monthly
Organisation of a Mentorship program and Masterclass to support young investigators starting out on their career path
Participation in a number of policy initiatives at European level
About The International Liver CongressTM 2014
The International Liver Congress™ 2014, the 49th annual meeting of the European Association for the study of the Liver, is being held at ExCel London from April 9 – 13, 2014. The congress annually attracts in excess of 9000 clinicians and scientists from around the world and provides an opportunity to hear the latest research, perspectives and treatments of liver disease from principal experts in the field.
For further information on the studies, or to request an interview, please do not hesitate to contact the EASL Press Office on:
Email: easlpressoffice@cohnwolfe.com
Helena Symeou +44 7976 562 430
Courtney Lock +44 7894 386 422
References
1. X.FORNS ET AL. SOFOSBUVIR COMPASSIONATE USE PROGRAM FOR PATIENTS WITH SEVERE RECURRENT HEPATITIS C INCLUDING FIBROSING CHOLESTATIC HEPATITIS FOLLOWING LIVER TRANSPLANTATION. ABSTRACT PRESENTED AT THE INTERNATIONAL LIVER CONGRESS™ 2014
2. M.GAMBATO ET AL. LONG TERM OUTCOME OF MILD HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION: A LARGE PROSPECTIVE STUDY. ABSTRACT PRESENTED AT THE INTERNATIONAL LIVER CONGRESS™ 2014
3. EU BURDEN OF LIVER DISEASE: A REVIEW OF AVAILABLE EPIDEMIOLOGICAL DATA. EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER. 2013. HTTP://WWW.EASL.EU/ASSETS/APPLICATION/FILES/54AE845CAEC619F_FILE.PDF ACCESSED 16.02.14.
New data reveals positive outcomes for hepatitis C transplant patients
2014-04-11
ELSE PRESS RELEASES FROM THIS DATE:
Viral hepatitis more deadly than HIV in Europe
2014-04-11
London, UK, Friday 11 April 2014: Mortality from viral hepatitis is significantly higher than from HIV/AIDS across EU countries, according to results from The Global Burden of Disease Study 2010 (GBD 2010) which was announced for the first time today at the International Liver CongressTM 2014(1).
GBD 2010 is the most recent version of a large epidemiological study funded by the Bill and Melinda Gates Foundation and coordinated by the Institute for Health Metrics and Evaluation (IHME) at the University of Washington.
In the EU, in 2010, there were more than 10 times ...
Immunotherapy could help tackle tough liver cancer
2014-04-11
London, England, Friday 11 April 2014 Significant new data presented today at the International Liver Congress™ 2014 indicate that liver cancer (Hepatocellular Carcinoma (HCC)) may be treated by adoptive T-cell therapy.
This new therapeutic approach in the treatment of HCC could be very important as without treatment the 5 year survival rate is just 5%. Globally, HCC accounts for 746,000 deaths, and in the UK alone is responsible for over 4,000 deaths per year.
Glypican-3 (GPC3) is a tumour associated antigen expressed in up to 70% of HCC but not in healthy human tissue. ...
Tamiflu & Relenza: How effective are they?
2014-04-11
Tamiflu (the antiviral drug oseltamivir) shortens symptoms of influenza by half a day, but there is no good evidence to support claims that it reduces admissions to hospital or complications of influenza. This is according to the updated Cochrane evidence review, published today by The Cochrane Collaboration, the independent, global healthcare research network and The BMJ. Evidence from treatment trials confirms increased risk of suffering from nausea and vomiting. And when Tamiflu was used in prevention trials there was an increased risk of headaches, psychiatric disturbances, ...
NASA sees hurricane-strength Tropical Cyclone Ita heading toward Queensland
2014-04-10
VIDEO:
On April 9, NASA's TRMM saw powerful storms in Ita's eye wall reached heights of over 14 km/8.7 miles. The tallest thunderstorm towers reached heights of over 16 km/9.9 miles...
Click here for more information.
Tropical Cyclone Ita has been strengthening over the last two days and by April 10, Ita had become a major hurricane in the Coral Sea when NASA's Terra satellite passed overhead.
Ita's maximum sustained winds were near 115 knots/132 mph/213 kph on April 10 at 0900 ...
Appearance of night-shining clouds has increased
2014-04-10
First spotted in 1885, silvery blue clouds sometimes hover in the night sky near the poles, appearing to give off their own glowing light. Known as noctilucent clouds, this phenomenon began to be sighted at lower and lower latitudes -- between the 40th and 50th parallel -- during the 20th century, causing scientists to wonder if the region these clouds inhabit had indeed changed -- information that would tie in with understanding the weather and climate of all Earth.
A NASA mission called Aeronomy of Ice in the Mesosphere, or AIM, was launched in 2007 to observe noctilucent ...
NASA simulation portrays ozone intrusions from aloft
2014-04-10
Outdoor enthusiasts in Colorado's Front Range are occasionally rewarded with remarkable visibility brought about by dry, clear air and wind. But it's what people in the mountainous U.S. West can't see in conditions like this – ozone plunging down to the ground from high in the stratosphere, the second layer of the atmosphere – that has attracted the interest of NASA scientists, university scientists and air quality managers.
Ozone in the stratosphere, located on average 10 to 48 kilometers (6 to 30 miles) above the ground, typically stays in the stratosphere. Not on days ...
NASA's Hubble extends stellar tape measure 10 times farther into space
2014-04-10
Using NASA's Hubble Space Telescope, astronomers now can precisely measure the distance of stars up to 10,000 light-years away -- 10 times farther than previously possible.
Astronomers have developed yet another novel way to use the 24-year-old space telescope by employing a technique called spatial scanning, which dramatically improves Hubble's accuracy for making angular measurements. The technique, when applied to the age-old method for gauging distances called astronomical parallax, extends Hubble's tape measure 10 times farther into space.
"This new capability ...
SU plays key role in search for elusive dark matter
2014-04-10
Physicist Richard Schnee hopes to find traces of dark matter by studying particles with low masses and interaction rates, some of which have never been probed before.
The ongoing search for invisible dark matter is the subject of a recent article involving physicists from Syracuse University's College of Arts and Sciences.
Research by Richard Schnee, assistant professor of physics, is referenced in Symmetry magazine, a joint publication of the Stanford Linear Accelerator Center in Palo Alto, Calif., and Fermilab in Batavia, Ill.
"Scientists looking for dark matter ...
SU geologists prove early Tibetan Plateau was larger than previously thought
2014-04-10
Earth scientists in Syracuse University's College of Arts and Sciences have determined that the Tibetan Plateau—the world's largest, highest, and flattest plateau—had a larger initial extent than previously documented.
Their discovery is the subject of an article in the journal Earth and Planetary Science Letters (Elsevier, 2014).
Gregory Hoke, assistant professor of Earth sciences, and Gregory Wissink, a Ph.D. student in his lab, have co-authored the article with Jing Liu-Zeng, director of the Division of Neotectonics and Geomorphology at the Institute for Geology, ...
SU professors test boundaries of 'new physics' with discovery of 4-quark hadron
2014-04-10
Physicists in Syracuse University's College of Arts and Sciences have helped confirm the existence of exotic hadrons—a type of matter that cannot be classified within the traditional quark model.
Their finding is the subject of a forthcoming article, prepared by the Large Hadron Collider beauty (LHCb) Collaboration at CERN in Geneva, Switzerland. (LHCb is a multinational experiment, designed to identify new forces and particles in the universe.) Tomasz Skwarnicki, professor of physics, is one of the paper's lead authors.
"We've confirmed the unambiguous observation ...